Innocell™

About PhotonPharma

PhotonPharma is a private, pre-revenue biotech focused on a novel cell therapy platform that uses light (riboflavin and UV) to create replication-incompetent tumor cells from a patient's own tumor sample. This 'Innocell' product serves as a personalized vaccine, presenting the full spectrum of a patient's tumor neoantigens to stimulate a potent and broad anti-cancer immune response. The company has received FDA clearance to initiate a Phase 1 safety and immunogenicity study in recurrent epithelial ovarian cancer, marking a key transition from preclinical validation to clinical development. Leadership includes seasoned veterans from academia, medical device, and pharmaceutical regulatory affairs, providing a blend of scientific innovation and industry execution expertise.

Therapeutic Areas